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Abstract
Background Transplantation of mesenchymal stem cells
(MSCs) is one possible strategy to achieve articular carti-
lage repair. We previously reported that synovial MSCs
were highly proliferative and able to undergo chondroge-
nesis. We also found that placing a suspension of synovial
MSCs on a cartilage defect for 10 minutes promoted car-
tilage repair in rabbit and pig models. However, the in vivo
efficacy of this approach has not been tested clinically.
Questions/purposes We asked whether transplantation of
synovial MSCs improves (1) MRI features, (2) histologic
features, and (3) clinical evaluation scores in patients with
cartilage defects in the knee?
Methods Patients with a symptomatic single cartilage
lesion of the femoral condyle were indicated for inclusion in
our study, and between April 2008 and April 2011, 10
patients were enrolled in this study. All patients completed
followups of 3 years or more. The average followup period
was 52 months (range, 37–80 months). Synovial MSCs
were expanded with 10% autologous human serum for
14 days after digestion. For transplantation, the patient was
positioned so that the cartilage defect was facing upward,
and synovial MSC suspension was placed on the cartilage
defect with a syringe under arthroscopic control. The defect
with the applied suspension then was held in the upward
position for 10 minutes. Five patients underwent concomi-
tant ACL reconstructions, among whom two had meniscus
suturing performed simultaneously. For MRI quantification,
the cartilage defect was scored from 0 to 5. Second-look
arthroscopy was performed for four patients and biopsy
specimens were evaluated histologically. Clinical outcome
was assessed using the Lysholm score and Tegner Activity
Level Scale at final followup. Comparisons of MRI and
Lysholm scores before and after treatment for each patient
were analyzed using the Wilcoxon signed-rank test.
Results MRI score (median ± 95% CI) was 1.0 ± 0.3
before and 5.0 ± 0.7 after, and increased after treatment in
each patient (p = 0.005). Second-look arthroscopy in four
patients showed that the cartilage defect appeared to be
qualitatively better in all cases. Histologic analyses showed
hyaline cartilage in three patients and fibrous cartilage in
one at the deep zone. The Lysholm score (median ± 95%
CI) was 76 ± 7 before and 95 ± 3 after, and increased
after treatment in each patient (p = 0.005). The Tegner
Activity Level Scale did not decrease after treatment in
each patient.
Conclusions For this small initial case series, transplan-
tation of synovial MSCs was effective in terms of MRI
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score, qualitative histology, and Lysholm score. The use of
synovial MSCs has an advantage in that the cells can be
prepared at passage 0 in only 14 days. Transplantation of
synovial MSCs may be less invasive than mosaicplasty and
autologous chondrocyte implantation. To conclusively
show the effectiveness of this treatment requires com-
parative studies, especially with more established
arthroscopic procedures, such as marrow stimulation
techniques.
Level of Evidence Level IV, therapeutic study.
Introduction
Articular cartilage injuries are a common clinical problem
and if left untreated, may lead to osteoarthritis. Although
there are various methods for surgical intervention, each
has respective disadvantages: poor structural quality of the
repaired cartilage in bone marrow stimulation, donor site
morbidity in mosaicplasty, and loss of chondrogenic
phenotype of expanded chondrocytes in autologous chon-
drocyte implantation [13]. Stem cell therapy may be one
possible strategy for improving repair of cartilage injuries.
One of the candidate therapeutic cells is mesenchymal stem
cells (MSCs), which can be isolated from various mes-
enchymal tissues. Previous in vitro [21] and in vivo [8]
chondrogenic assays showed that synovial MSCs had su-
perior chondrogenic ability compared with MSCs from
other tissues. Synovial MSCs also expanded well in the
presence of human serum [19]. Finally, in rabbit [9] and
pig [16] studies, transplantation of synovial MSCs pro-
moted cartilage regeneration; therefore, synovial MSCs
appear to be a promising cell source for cartilage repair.
The synovium is a thin membrane that covers the inside
of the joint and has high regenerative potential [4].
According to previous studies, the number of MSCs in
synovial fluid increased in knees with ACL injury [14],
meniscus injury [12], and osteoarthritis [24]. The mor-
phologic features and gene profiles of the MSCs released in
synovial fluid after a joint injury were more similar to
synovial MSCs than bone marrow MSCs. Principal com-
ponent analysis of gene profiles for various mesenchymal
tissue-derived MSCs and chondrocytes showed that MSCs
from intraarticular tissues and chondrocytes were closer to
each other than MSCs from extraarticular tissues [23].
Embryologically, chondrocytes and synovial cells share a
similar progenitor-cell population [1]. Synovial MSCs
which were injected intraarticularly attached to the injured
site and promoted healing to various degrees in a rabbit
cartilage-defect model [9]. The findings suggest that the
synovium is a reservoir for MSCs that can contribute to
intraarticular tissue repair. After intraarticular tissues like
cartilage are injured, MSCs may be mobilized from the
synovium to the synovial fluid, adhere to the injured site,
and contribute to its repair. However, native MSCs are
limited in quantity; this is likely the reason that injured
articular cartilage generally does not heal. Transplantation
of synovial MSCs in large numbers to injured tissues may
promote a natural healing process for injured tissues
including articular cartilage.
Various methods have been used to transplant MSCs in
cartilage defects, such as intraarticular injection and
transplantation, with or without the use of scaffolds [13]. It
was shown that placing a suspension of synovial MSCs on
the cartilage defect and leaving the cartilage defect
immobilized for 10 minutes resulted in approximately 60%
of the cells adhering to the defect to promote cartilage
repair in rabbit [9, 25] and pig [16] knee models. The other
40% of synovial MSCs were taken up by adjacent synovial
tissues, with no adverse effects on the synovium or other
tissues in the knee. This technique for use of synovial cells
can be performed arthroscopically without the need for
synthetic or natural scaffolds. On the basis of more than 50
promising basic and preclinical research studies [3], we
began arthroscopic transplantation of autologous synovial
MSCs for cartilage defects in the knee.
We believe this is the first report of a clinical study
performed with synovial MSCs; as such, the in vivo effi-
cacy of this approach, to our knowledge, has not been
tested. We asked whether transplantation of synovial MSCs
improves (1) MRI features, (2) histologic features, and (3)
clinical evaluation scores in patients with cartilage defects
in the knee?
Patients and Methods
Our study was approved by the ethics committee of our
university. Eligible patients were 20 years old or older with
a symptomatic single cartilage lesion of the femoral con-
dyles (Table 1). Ten patients were enrolled in this study,
and the cause of the cartilage defect primarily was trauma
for all 10. The first patient was enrolled in April 2008 and
the last in April 2011. All completed followups for 3 years
or more. The median age of the patients was 41 years
(range, 20–43 years); median duration of symptoms was
3 years (range, 0.6–16 years); median size of each carti-
lage defect was 200 mm2 (range, 25–500 mm2); and
median followup was 48 months (range, 36–80 months).
The inclusion criteria included ‘‘symptomatic International
Cartilage repair Society (ICRS) Grades 3 and 4 cartilage
single lesions of the femoral condyles’’ and the exclusion
criteria included ‘‘less than 6 months with symptom’’,
‘‘patellofemoral cartilage lesion’’, and ‘‘microfracture per-
formed’’ (Table 2). Five patients underwent ACL
reconstructions, among whom two had meniscus sutures
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performed simultaneously with the synovial MSC
transplantation.
One or 2 days before synovial tissue was harvested,
approximately 300 mL of whole blood was obtained from
all donors using Cellaid1 (JMS Co Ltd, Hiroshima, Japan),
a closed-bag system for isolation of serum (Fig. 1). The
system consists of a blood donation bag containing glass
beads which function by activating platelets and removing
fibrin from whole blood through a 30-minute, gentle mix-
ing process. After centrifugation at 2000 g for 7 minutes,
the serum was isolated and heat inactivated at 56 C for
30 minutes. The serum was filtered through a 0.45-lm
nylon filter (Becton Dickinson, Franklin Lakes, NJ, USA)
and stored at 4 C until use [19].
Arthroscopy was performed to observe cartilage defects
in Patients 1, 8, 9, and 10, who received local anesthesia
with 20 mL 1% xylocaine. Then, with the patient under
intravenous anesthesia with 0.1 g sodium pentothal, the
synovium with subsynovial tissue on the femur at the
suprapatellar pouch was harvested with a pituitary rongeur
under arthroscopic observation (Fig. 1). Patients were
discharged from the hospital after synovium harvest. For
Patients 2 through 7 who received lumbar spinal anesthe-
sia, the synovium with subsynovial tissue was harvested
before ACL reconstruction, medial meniscus suture, or
removal of free bodies was performed.
The cell culture was performed in the cell processing
center at the authors’ institution. The cell processing center
acquired ISO9001 certification, the international standard
for quality management systems, in 2004. The synovium
was digested in a solution of 5 mg LiberaseTM (Roche
Diagnostics, Mannheim, Germany) in 5 mL Hanks’
Balanced Salt Solution (HBSS; Invitrogen, Carlsbad, CA,
USA) at 37 C (Fig. 1). After 3 hours, the digested cells
were filtered through a 70-lm nylon filter (Becton Dick-
inson). The cells were cultured in a-MEM (Invitrogen),
containing 10% autologous human serum, 100 units/mL
penicillin, 100 lg/mL streptomycin, and 250 ng/mL
amphotericin B. At 12 days, two among approximately 50
dishes were selected to examine bacteria, endotoxin in the
medium, mycoplasma, and virus in the cells. For bacterial
testing, chocolate agar was used. For endotoxin testing, a
Toxicolor1 LS-50M kit (Seikagaku Corporation, Tokyo,
Japan) was used [26]. For mycoplasma and virus tests,
























1 26 M 2 225 ACL reconstruction,
MM removal
MFC 3 63 43
2 43 M 3 500 Removal of free body Osteochondral defect LFC 72 80 7
3 26 M 9 162 ACL reconstruction MM partial worn MFC 12 47 34
4 21 M 4 54 ACL reconstruction MM partial worn MFC 12 37 77
5 42 F 16 500 ACL reconstruction MM partial worn MFC 6 56 39
6 20 F 1 25 ACL reconstruction,
MM suture
MFC 3 65 72
7 41 F 3 200 ACL reconstruction,
MM suture
MFC 3 49 40
8 40 F 0.6 120 MFC 24 44 50
9 41 M 8 400 LM removal LFC 24 37 70
10 41 F 0.7 200 MFC 24 39 40
MSC = mesenchymal stem cell; MM = medial meniscus; LM = lateral meniscus; MFC = medial femoral condyle; LFC = lateral femoral
condyle.
Table 2. Inclusion and exclusion criteria
Inclusion criteria
Patients provided written informed consent
20 years of age and older
Symptomatic cartilage single lesions of the femoral condyles
ICRS Grades 3 (cartilage defects extending down[ 50% of
cartilage depth) and 4 (bone defect)
Exclusion criteria








Poor general health condition
ICRS = International Cartilage Repair Society.
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a multiplex PCR system developed by our team was used
[6]. This system made it possible to detect 142 types of
mycoplasma and 17 types of virus. One dish also was used
for chromosomal testing.
After no contamination with bacteria, mycoplasma,
virus, or endotoxin was confirmed, synovial MSCs were
harvested at 14 days (Fig. 1D) with TrypLETM (Invitro-
gen) at 37 C for 5 minutes. Thirty minutes before
transplantation, primary synovial MSCs were suspended in
0.5 mL acetate Ringer’s solution (Veen-3G; Kowa, Tokyo,
Japan) [25]. The number of transplanted cells was
47 ± 21 million (mean ± SD).
With the patient under lumber spinal anesthesia, the
surface of the cartilage legion was arthroscopically scrat-
ched with curettage for de´bridement, but bleeding from the
subchondral bone was avoided. The knee then was moved
so the cartilage defect was facing upward (Figs. 1E, 2A),
and irrigation fluid was completely drained from the knee
(Fig. 2B). A suspension of synovial MSCs in 0.5 mL
acetate Ringer’s solution was placed in the defect through
an 18-gauge needle attached to a 1-mL syringe (Fig. 2C).
The patient was maintained in position for 10 minutes [9,
25]. The incisions for the portals then were closed without
washing the inside of the knee.
All patients started ROM exercise of the knee 1 day after
the procedure, were partial weightbearing at 2 weeks, and
full weightbearing at 6 weeks. Special equipment such as a
continuous passivemotionmachinewas not used. Generally,
low-impact activities started at 3 months and high-impact




Fig. 1A–E Preparation of synovial MSCs for arthroscopic transplan-
tation is shown. (A) Peripheral blood was collected for autologous
human serum. (B) Synovium was harvested with a pituitary rongeur
under arthroscopic observation. (C) Synovium was digested at a cell
processing center. (D) Synovial MSCs were expanded with 10%
autologous human serum. (E) Passage 0 synovial MSCs were
transplanted arthroscopically.
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All MRI examinations were performed on a 3.0-T
Gyroscan Intera MR unit (Philips Medical Systems, Best,
The Netherlands). MR images were taken with 10 flexion
of the knee. For quantification, grading for ‘‘degree of
defect repair and filling of the defect’’ as described by
Marlovits et al. [11] was modified as ‘‘cartilage defect’’ for
the purposes of our study. This score was evaluated by two
independent observers (MH, KO) in a blinded manner.
Sagittal and coronal MR images were assessed preop-
eratively and 3 months postoperatively for each patient.
MRI followup was available for four of the 10 patients
at a minimum of 2 years (mean, 18 months; range,
3–72 months) (Table 1).
Second-look arthroscopy was done on four patients who
reported having discomfort with two staples on the tibia for
ACL reconstruction [15], with the procedure for removal of
staples at 11 to 18 months after transplantation of synovial
MSCs.After informed consentwas obtained, a needle biopsy
also was performed at the center of the repaired cartilage.
Biopsy specimens of the fragment were fixed in 4%
paraformaldehyde for 24 hours, embedded in paraffin, and
cut into 5-lm sections. The specimens were stained with
Safranin O and fast green and viewed with an Olympus1
MVX10 microscope (Olympus Corporation, Tokyo, Japan).
Cartilage matrix was described qualitatively.
Clinical outcomes were assessed using the Lysholm score
[10] and Tegner Activity Level Scale [27] at final followup.
Comparison of the MRI and Lysholm scores before and
after treatment for each patient were analyzed using the
Wilcoxon signed rank test. A p value less than 0.05 was
considered statistically significant.
Results
Based on MRI evaluations, cartilage defects were covered
with cartilaginous tissue with time (Fig. 3A–C [Patient 8]).
In some instances, cartilage defects already were covered
with cartilaginous tissue at 3 months and the repaired
cartilage was maintained thereafter (Fig. 3D–F [Patient
10]). MRI scores for cartilage defects increased after
treatment for all 10 patients, regardless of ACL recon-
struction (Fig. 3G). MRI scores were 1.0 ± 0.3 before and
5.0 ± 0.7 after the treatment (median ± 95% CI,
p = 0.005). Lateral femoral condyle defects were incom-
pletely healed in Patient 9, whose lateral meniscus
previously had been completely removed.
Patient 2 presented with an osteochondral defect of the
lateral femoral condyle and reported severe pain in the
knee before treatment. At 72 months, the bone defect
already was filled with bone-like tissue (Fig. 4A–C), and
the cartilage defect was incompletely filled with carti-
laginous tissue (Fig. 4D–F). The patient’s symptoms
gradually improved after transplantation of synovial
MSCs.
The repaired cartilage was examined arthroscopically
and histologically for the four patients who had staples for
ACL reconstruction removed (Fig. 5). The cartilage defect
Fig. 2A–C Arthroscopic transplantation of synovial MSCs is shown.
(A) The patient was positioned so that the cartilage defect faced
upward. This patient had a cartilage defect on the lateral femoral
condyle. His hip was flexed, adducted, and internally rotated to face
the cartilage defect upward. A suspension of synovial MSCs in
0.5 mL was placed in the defect through an 18-gauge needle attached
to a 1-mL syringe. (B) Irrigation fluid was completely drained from
the knee. (C) The synovial MSC suspension was placed on the
cartilage defect of the femoral condyle. The patient was maintained in
position for 10 minutes.
2320 Sekiya et al. Clinical Orthopaedics and Related Research1
123
Fig. 3A–G Sequential MRI features and the MRI scores for the
cartilage defects are shown. The cartilage lesion in Patient 8 is
indicated by the arrow (A) before treatment (B) at 6 months, and
(C) at 2 years. In Patient 10 the cartilage lesion is indicated by the
arrow (D) before treatment, (E) at 3 months, and (F) at 2 years.
(G) The MRI scores for the cartilage defects are shown (n = 10
patients; p = 0.005 by Wilcoxon signed rank test between MRI
scores before and after transplantation of synovial MSCs). ‘‘Bone
defect’’ is scored as 0; ‘‘Subchondral bone exposure’’ is scored as 1;
‘‘Cartilage defect extending down more than 50% of cartilage depth’’
is scored as 2; ‘‘Cartilage defect extending down to less than 50% of
cartilage depth’’ is scored as 3; ‘‘Cartilage hypertrophy’’ is scored as
4; and ‘‘Complete healing’’ is scored as 5. Patient number is indicated
by the key in the upper right, and the dotted lines indicate MRI scores
in patients with ACL reconstruction.
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appeared improved in all four (Fig. 5A–H). In Patient 3,
the surface of the repaired cartilage appeared hypertrophic
but was soft, although its deep zone was cartilaginous
(Fig. 5A, B); therefore, an additional procedure was not
performed. In Patient 4, the thickness of the cartilage defect
appeared to increase at 18 months (Fig. 5C, D). In Patient
5, the surface of the repaired cartilage consisted of fibril-
lated fibrous tissue (Fig. 5E, F), which was removed
because the patient reported a minor catching sensation
before the second-look arthroscopy. The symptom disap-
peared after the additional procedure. In Patient 7, the
thickness of the cartilage defect also appeared to increase
at 12 months (Fig. 5G, H).
Specimens from Patient 3 contained fibrous cartilage in
the deep zone and fibrous tissue in the surface zone
(Fig. 5I). Specimens from Patients 4, 5, and 7 contained
hyaline cartilage in the deep zone (Fig. 5J–L). However,
specimens from Patients 4 and 5 consisted of fibrous tissue
in the surface zone (Fig. 5J, K).
Lysholm knee scores improved after treatment in all
10 patients regardless of ACL reconstruction (Table 3).
The Lysholm score was 76 ± 7 before and 95 ± 3 after
the treatment (median ± 95% CI, p = 0.005). The
Tegner Activity Scale score did not decrease after the
treatment in all 10 patients (Table 3). There were no
complications observed up to 37 months at minimal
followup, except in Patient 5 who had fibrillation of the
repaired cartilage.
Discussion
MSCs provide promising candidate cells for therapy. In
this clinical study, we examined whether transplantation of
synovial MSCs improved MRI features, histologic features,
and clinical evaluation scores in patients with cartilage
defects in the knee. For this small, initial case series,
transplantation of synovial MSCs was effective in terms of
MRI, qualitative histologic findings, and Lysholm score.
Our study has four limitations. First, the study included
only 10 patients who presented with various preoperative
conditions. Five patients had ACL reconstructions, among
whom two had medial meniscus sutures performed simul-
taneously. The associated surgeries may have affected the
outcome of the transplantation. Second, the number of
patients for whom second-look arthroscopy and biopsy
results were available also was limited. Third, we observed
promising outcomes for use of synovial MSC transplanta-
tion, but longer-term observations will be necessary to fully
evaluate this new treatment. Fourth, we have not performed
Fig. 4A–F Sequential MRI features of Patient 2 who had an
osteochondral defect, indicated by the arrow, are shown (A) for bone
before treatment, (B) at 6 months, and (C) at 6 years, and for
(D) cartilage before treatment, (E) at 6 months, and (F) at 6 years.
The sequential MR images showed that the osteochondral defect was
filled with cartilaginous tissue at 6 months. The bone defect was filled
with bony tissue, and the cartilage defect was incompletely filled with
cartilaginous tissue at 6 years.
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prospective comparative randomized trials among synovial
MSCs, mosaicplasty, marrow stimulation, and chondrocyte
transplantation approaches and we did not use validated
patient-reported outcomes tools such as the Knee Injury
and Osteoarthritis Outcome Score [20]. These comparisons
and measures will be essential to show the effectiveness of
synovial MSC transplantation for routine clinical use.
Finally, while not strictly a limitation, this study included
one patient who previously had a total meniscectomy but
who did not receive a simultaneous meniscus replacement
(scaffold or allograft). This currently is considered an
exclusion criterion for autologous chondrocyte implanta-
tion, together with malalignment and laxity [2]. We started
this clinical study in 2008. At that time, excluding a patient
with a total meniscectomy, to our knowledge, was not the
standard course therefore the patient was included here.
Fig. 5A–L Arthroscopic and histologic assessments were performed
before and after transplantation of synovial MSCs. Arthroscopic
features for the cartilage in Patient 3 are shown (A) before treatment
and (B) at 11 months; for Patient 4 (C) before treatment and (D) at
18 months; for Patient 5 (E) before treatment and (F) at 14 months;
and for Patient 7 (G) before treatment and (H) at 12 months. (I) A
histologic section of the repaired cartilage obtained after a needle
biopsy at the center of the repaired cartilage in Patient 3 contained
fibrous cartilage in the deep zone and fibrous tissue in the surface
zone. (J) In Patient 4, the histologic section contained hyaline
cartilage in the deep zone and fibrous tissue in the surface zone.
(K) In Patient 5, the section contained hyaline cartilage in the deep
zone and fibrous tissue in the surface zone, and (L) in Patient 7, the
section contained hyaline cartilage in the deep zone (Stain, Safranin O
and fast green; Bar = 1 mm).
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For repair of cartilage, bone marrow stimulation,
mosaicplasty, and autologous chondrocyte implantation are
currently the most commonly performed procedures [14].
Bone marrow stimulation techniques such as microfracture
still represent a simple first-line option when performed in
young patients with small, single lesions, and low post-
operative demands; however, larger lesions and active
patients require an alternative procedure [13]. Mosaicplasty
and autologous chondrocyte implantation usually require
open surgery and the sacrifice of normal, healthy cartilage
tissue. The development of cartilage repair procedures that
are effective but minimally invasive is ongoing.
Bone marrow is currently the most common MSC
source used clinically. Wakitani et al. [30] performed a
prospective clinical study of bone marrow MSC trans-
plantation for cartilage repair in which passaged bone
marrow MSCs were resuspended in a collagen type I gel
and transplanted with an autologous periosteal flap in
patients with medial osteoarthritis in the knee who under-
went a high tibial osteotomy. They [31] also presented
three case reports where a bone marrow MSC-containing
scaffold with a periosteal flap was used. Nejadnik et al.
[18] performed an observational cohort study in which the
clinical outcomes of patients treated with autologous
chondrocyte implantation were compared with outcomes of
patients treated with autologous bone marrow MSCs. The
patients had the periosteum sutured to the cartilage defect
which was sealed with fibrin glue; bone marrow MSCs then
were implanted beneath the patch. Transplantation of bone
marrow MSCs improved the symptoms of the patients and
cartilage lesions [32].
Another possible problem related to the use of bone
marrow-derived MSCs for cartilage repair is phenotype
stability because of their intrinsic tendency to undergo
endochondral ossification and consequently calcify, forming
subchondral bone overgrowth or intralesional osteophytes.
We did not observe any subchondral bone overgrowth or
ectopic bone formation although we analyzed only 10 cases
by radiographs andMR images. It currently is not possible to
definitively conclude whether bone marrow MSCs or syn-
ovial MSCs produce more stable forms of cartilage.
From our study results, we propose three potential
advantages to using our procedure with synovial MSCs
instead of procedures with bone marrow MSCs. First, we
could prepare passage 0 synovial MSCs, expanded with
autologous human serum in 14 days, for transplantation.
We previously attempted to expand passage 0 synovial
MSCs and bone marrow MSCs with autologous human
serum. More than 10 million synovial MSCs were obtained
from all nine donors, contrary to more than 1 million bone
marrow MSCs from only two among nine donors [19]. In
the current study, we also were able to prepare more than
30 million synovial MSCs with autologous human serum
from nine of 10 patients and confirm no chromosomal
abnormality in synovial MSCs in all cases. Passage 0 cells
are safer than cells passaged several times in terms of the
probability of developing chromosome abnormalities [5].
In addition, the ability to prepare enough passage 0 cells in
14 days could reduce costs compared with the need to
passage cells multiple times for longer periods. Second, we
could transplant synovial MSCs arthroscopically, allowing
patients to return to daily life and sports activities earlier
than those with more open surgery. Third, scaffolds were
not used in our current procedure, which can reduce pos-
sible risks such as foreign body reactions [17] and delay the
natural healing process [8]. In the current clinical study, the
maximum size of the lesion was 500 mm2. For larger de-
fects, some modification may be required.
Table 3. Outcomes before and after transplantation of synovial MSCs
Patient Lysholm score Tegner activity scale Activity
Before* After* Before After
1 76 81 7 7 Recreational soccer
2 48 95 5 5 Heavy labor
3 62 95 4 4 Cycling
4 80 95 7 7 Recreational basketball
5 73 95 7 7 Recreational basketball
6 76 94 6 6 Recreational volleyball
7 76 90 6 6 Physical education
8 75 100 6 6 Recreational tennis
9 86 95 6 6 Recreational tennis
10 86 100 3 3 Light labor
* Lysholm scores before and after transplantation were 76 ± 7 and 95 ± 3 (median ± 95% CI, p = 0.005 by Wilcoxon signed-rank test).
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The repair process for osteochondral defects after
transplantation of synovial MSCs is of considerable inter-
est. In a rabbit study, osteochondral defects were first filled
with cartilage matrix, then the integrated border region
between bone and cartilage progressed upward, and finally,
the entire thickness of the regenerated cartilage became
similar to that of the neighboring cartilage [7]. A similar
repair process was reported with bone marrow MSCs in a
rabbit model [28]. By contrast, when chondrocytes were
transplanted, the osteochondral defect was filled with car-
tilage matrix and this was preserved without remodeling
[29]. In the current study, Patient 2 had an osteochondral
defect. According to MRI examinations, the defect
appeared to be filled with cartilaginous tissue at 6 months,
then the bone defect was almost completely filled with
bony tissue and the surface of the lateral femoral condyle
was partially covered with cartilaginous tissue thereafter
(Fig. 5). Similar repair processes were observed in the
osteochondral defect after transplantation of synovial
MSCs in rabbits and humans although it required a longer
time in humans than in rabbits.
According to histologic biopsy specimen analyses,
fibrous tissue was observed at the surface in three of four
specimens. Nakamura et al. [16] reported that placing a
synovial MSC suspension on the osteochondral defect for
10 minutes promoted cartilage repair, and sequential
arthroscopic observations showed the cartilage defect was
first covered with the formation of a membrane before
cartilage repair in a pig model. In the current clinical study,
11, 12, 14, and 18 months may be too short for the repaired
cartilage to mature after transplantation of synovial MSCs.
Even in chondrocyte implantation, 12 months seemed to be
too short for the repaired cartilage to mature according to
histologic analyses [22].
We found that we could prepare an average of 47 million
passage 0 synovial MSCs expanded with autologous human
serum. Synovial MSCs could be transplanted arthro-
scopically without a scaffold. For this small, initial case
series, transplantation of synovial MSCs was effective in
terms ofMRI, arthroscopic or histologic qualitative findings,
and Lysholm score. Transplantation of synovial MSCs may
be less invasive than mosaicplasty and autologous chon-
drocyte implantation. The conclusive observation of the
effectiveness of this treatment will require comparative
studies, especially with more established arthroscopic pro-
cedures, such as marrow stimulation techniques.
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